Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
Completed
Forest Laboratories
Phase 3
2016-03-31
This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of
cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the
depressive episode in participants with bipolar I disorder. The safety and tolerability of
the fixed-dose regimens will be evaluated.
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
Completed
Forest Laboratories
Phase 3
2016-03-17
This study investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 milligram
(mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in
participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens
will be evaluated.
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
Completed
Forest Laboratories, LLC, an Allergan Affiliate
Phase 3
2016-03-17
This study investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 milligram
(mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in
participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens
will be evaluated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
